amp biosimilars announces Klaus K. Wilgenbus as new CEO

  • Experienced industry executive to start as new CEO on July 1
  • Founding CEO Marc W. Hentz steps down in a planned succession move
Hamburg, Germany, June 28 2016 – amp biosimilars AG (ISIN: DE000A0SMU87), a company specializing in the development of high-quality biosimilars, today announced that Klaus K. Wilgenbus will lead the firm as the new CEO from July 1, 2016. In 2014 Klaus Wilgenbus retired as Corp. Senior VP Business Development Licensing and Strategy from Boehringer Ingelheim (BI). During his 18 year tenure at BI he held various positions covering Business Development, R&D, innovation management, corporate and commercial strategy, and organizational development. Under his leadership BI has entered into more than 200 strategic transactions incl. R&D collaborations, global co-promotion and co-marketing alliances, JV’s and merger and acquisitions with business partners from North-America, EU and Asia. Klaus Wilgenbus also served on various boards such as Karolinska Development AB (Solna Sweden), Actimis Inc. (San Diego) and Boehringer Ingelheim Deutschland GmbH & Co KG and represented BI at the Board of (US) BIO. After 2014 Klaus Wilgenbus served as interim-CEO at Karolinska Development AB and advised as independent consultant small to mid sized biotech companies and life sciences investors in the areas of corporate strategy, fundraising and business transactions. Wilgenbus was trained as a physician in Germany and the US and holds an MD from RWTH Aachen. “It’s an exciting time to be joining amp biosimilars, with the company’s product and deal pipeline growing rapidly” said Wilgenbus. “I look forward to joining the amp team in order to advance the development of new high-quality therapies for patients in both the pharmerging and the regulated markets, the primary focus of the work at amp.” Founding CEO Dr. Marc W. Hentz retires from the post in a planned succession move. “I am excited that we can implement our plan to attract an experienced industry leader to join amp for its next phase of corporate development. The Board’s appointment of Klaus Wilgenbus is a testimony to our success and strategic direction, and I sincerely congratulate him. Klaus is an experienced biopharma executive and an outstanding dealmaker whose skill-set will directly contribute to the firm’s future growth path. As a founder and shareholder I am excited about his future impact on the company and will continue to support amp in any advisory or other capacity required.” Chairman of amp Supervisory Board Dr. Thomas Zimmer comments: “With Klaus Wilgenbus we have identified a leading pharma executive who brings a tremendous wealth of pharma and biotech knowhow to amp biosimilars AG. The addition of his business acumen enhances our ability to deliver high-value biosimilars for the future. I thank Marc Hentz for his 2 years of successful leadership in building the company and securing its first out licensing deals, and I am sure that Klaus Wilgenbus will ensure the continued expansion of our position as leader in biosimilar development.” About amp biosimilars AG: amp biosimilars AG develops high quality biosimilars to meet growing demand on global therapeutic markets and is one of the most innovative and dynamic biosimilar companies in Europe. The company is headquartered in Hamburg and run by a team of leading industry experts. The development of a wide variety of biosimilars will provide patients around the world with access to life-improving and life-saving therapies. The combination of a research platform with state-of-the-art analytics, process technology and clinical expertise as well as regulatory know-how, makes amp biosimilars AG one of the leading companies for biosimilar development and marketing. Thanks to an international network of leading pharmaceutical companies, amp biosimilars AG also has direct access to the strongest growing markets in the world. With this approach amp biosimilars AG has a key position in one of the fastest growing life science markets in the near future. amp biosimilars AG has been listed on the Munich Stock Exchange since April 1, 2015.

Stay up to date


This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Bitcoin AG and does not constitute a prospectus of Northern Bitcoin AG. The information contained in this press release is not intended to form the basis of any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As with all business and  nvestment matters, please consult qualified professional advice. This release and the information contained herein are not for distribution, directly or indirectly, in or into Canada, Australia or Japan.

Press Contact

Dr. Hans Joachim Dürr
Head of Corporate Communications
Phone: +49 69 348 752 89

Investor Relations

Sven Pauly
Phone: +49 89 125 09 03 31

Latest news

New opportunities to pay with Bitcoin

With the focus on Bitcoin as a digital preserver of value, its function as a means of payment seems to have taken a back seat. Here too, however, solutions are being developed to increase the speed of transactions, and the network of companies which accept Bitcoin in payment is constantly

Read More »

One third of US investors are considering Bitcoin purchases

Over a third (36%) of US investors would consider an investment in Bitcoin. What attracts them in particular is that they can start by investing small sums in Bitcoin. The potential for growth and the limited availability also argue in favor of an investment in Bitcoin. These are the principal

Read More »

Corporate News

Northern Bitcoin Publishes Annual Report 2018

Frankfurt am Main, July 23, 2019. Northern Bitcoin AG (XETRA: NB2, ISIN: DE000A0SMU87), one of the world’s leading companies in the sustainable mining of Bitcoin, today published its 2018 Annual Report. It is the first annual report following the realignment of the business purpose as a Bitcoin mining company in

Read More »

Northern Bitcoin doubles its mining capacities

Acquisition of 4,475 ASIC Miners Doubling of existing mining capacities Further significant expansion steps ahead of completion Frankfurt am Main, Germany – July 01, 2019. Northern Bitcoin AG (XETRA: NB2, ISIN: DE000A0SMU87), one of the world’s leading companies in the sustainable mining of bitcoin, has signed a purchase agreement for

Read More »